Navigation Links
Biomodels Expands Efforts in Cancer Supportive Care, Pulmonary Fibrosis; Preclinical Research Organization Names Dr. Stephen T. Sonis as Partner
Date:7/22/2009

WATERTOWN, Mass., July 22 /PRNewswire-USNewswire/ -- Biomodels LLC, a pre-clinical research organization best known for its expertise in oral mucositis, today announced it will further increase its work in the areas of cancer supportive care, pulmonary fibrosis, and biphosphonate-related osteoncrosis, with the promotion of Stephen T. Sonis DMD, DMSc to partner.

Dr. Sonis, a world-renowned expert in the clinical treatment and research of cancer regimen-related mucosal toxicities, said the company's collaborative work with pharmaceutical and biotechnology clients in the area of cancer supportive care is expected to grow sharply this year.

"The side effects of cancer treatment are becoming increasing important, as pharmaceutical and biotechnology companies realize that more effective dosing regimens can be achieved if side effects are considered and ameliorated at the pre-clinical stage," Dr. Sonis said.

Biomodels (www.biomodels.com) researchers have identified common mechanisms underlying toxicities that can lead to more rapid pharmaceutical interventions.

"Few people have the opportunity to help take a molecule from inception to patients, especially patients with great clinical need," Dr. Sonis said. "Biomodels' success in assisting industry to make the transition from test tube to the clinic as smoothly, quickly, safely and predictably as possible has been exciting for me.

"I look forward to our continued development of innovative models that expedite the clinical development process, especially to meet the challenges posed by regimen-related toxicities of cancer therapy," he added.

Biomodels is internationally known for its work in developing predictive animal models that are helping to determine which patients are predisposed to mucositis, osteonecrosis, cancer treatment-related thrombosis, gastrointestinal toxicity, pulmonary fibrosis, and salivary gland changes.

Dr. Sonis is widely recognized for his studies on the molecular and cellular pathogensis of mucositis, which have resulted in identifying a number of promising pharmaceutical targets to alleviate this universal and incapacitating side of effects of cancer treatment.

He has served as chief medical officer of Biomodels since it was founded in 1997, and holds appointments with the Harvard School of Dental Medicine, the Dana-Farber Cancer Institute, and Brigham and Women's Hospital.

He is the author of more than 100 original publications, 40 reviews and chapters, and seven books. Dr. Sonis serves on a number of editorial boards, and is a founding member of the International Society of Oral Oncology.

About Biomodels

Biomodels (www.biomodels.com), a preclinical contract research organization founded in 1997, has developed and conducted preclinical studies for biotechnology and pharmaceutical companies, particularly in the areas of cancer, cancer supportive care, radiation, therapy, and inflammatory diseases.

The company specializes in (non-GLP) predictive studies that evaluate efficacy and define mechanism of action, enabling clients to expedite the drug discovery process. Biomodels' preclinical studies anticipate clinical objectives and enable organizations to rapidly achieve preclinical milestones.

Photo available upon request.


'/>"/>
SOURCE Biomodels LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ATS Medical Expands Open Pivot Heart Valve Offerings
2. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
3. BioLife Solutions Expands Scientific Advisory Board
4. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
5. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
6. Pharsight Expands Strategic Consulting Services Team
7. Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
8. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
9. AQUISS Expands Into Significant New Territory
10. NanoBio Expands Drug Development Team for Its Anti-Infective Products
11. BitWine (TM) Nutrition Advisors Network Expands Roster of Licensed Dietitians and Nutritionists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 4, 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... and commercialization of targeted antiviral therapies, announced today that ... 2016, to be held February 8-9, 2016, at the ... Disruptive Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ...
(Date:2/4/2016)... ... ... Many of the engineers at FireflySci, Inc. have been manufacturing quartz and ... cuvette manufacturers is their supercharged customer service and their extensive database of glass cuvette ... of inside information, they have recently revamped their manufacturing techniques to reduce lead times ...
(Date:2/3/2016)... 3, 2016 Harvard Apparatus Regenerative Technology, ... developing bioengineered organ implants for life-threatening conditions of ... CEO Jim McGorry , will present at ... on Tuesday, February 9, 2016 at 8:00 am ... . HART,s presentation will be webcast live and ...
(Date:2/3/2016)... Milpitas, Calif. (PRWEB) , ... February 03, 2016 ... ... supply chain events annual report which summarizes and analyzes nearly 750 ... global event monitoring, alert, and analysis service. , Supply chain risk management ...
Breaking Biology Technology:
(Date:1/22/2016)... 2016 http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ... Market 2016-2020"  report to their offering. ... http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the addition ...
(Date:1/21/2016)... 21, 2016 --> ... market research report "Emotion Detection and Recognition Market by Technology ... (Facial Expression, Voice Recognition and Others), Services, Application ... to 2020", published by MarketsandMarkets, the global Emotion ... USD 22.65 Billion by 2020, at a CAGR ...
(Date:1/20/2016)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce the attainment of record-setting ... result of the company,s laser focus on (and growing ... it,s comprehensive, easy-to-use and highly affordable cloud-based technology platform. ... MedNet growth achievements in 2015 include: , ...
Breaking Biology News(10 mins):